Today: 29 April 2026
Browse Category

NYSE:ABBV 10 January 2026 - 26 January 2026

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie shares rose about 0.5% to $221.89 in after-hours trading Wednesday after executives outlined plans to expand into obesity treatments. The company is betting on GUBamy, a drug licensed from Denmark’s Gubra, and highlighted its focus on amylin-based therapies. Investors are watching for pricing pressure from Washington ahead of AbbVie’s Feb. 4 earnings report.
15 January 2026
··
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
1 2 3 4 5

Stock Market Today

  • European Stocks Rise as Oil Prices Climb Amid Iran Conflict Concerns
    April 28, 2026, 9:58 PM EDT. European shares climbed on Thursday following losses in Asian markets, driven by rising oil prices sparked by escalating tensions around Iran. The spike in crude prices raised concerns over supply disruptions, bolstering energy stocks while weighing on more sensitive sectors. Traders remain cautious as geopolitical risks add volatility. The move dampens some risk appetite but underlines how conflicts in key oil-producing regions can impact global markets immediately.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop